Scientific intelligence record
Experience 2.0
GLP-1 receptor agonist
Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist studied in type 2 diabetes. WPF organizes the available work by glycemic outcomes, cardiovascular outcomes, comparisons, and safety. Results depend on the population, comparator, dose, and follow-up period.
Record status
Traceability partial
Last meaningful update: 9/23/2026
Ranked research corpus
500
Categorized publications with transparent machine-proposed ranking; human appraisal pending.
global evidence atlas
This is a deduplicated literature screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.
500 matching records · ranked 2026-09-18
Page 1 of 20
Metabolism open · 2024 Jun · PMID 38699397 · DOI 10.1016/j.metop.2024.100284
Type 2 diabetes and glycemia · Safety and tolerability · Comparative effectiveness
American journal of therapeutics · 2024 Jul-Aug 01 · PMID 38976545 · DOI 10.1097/MJT.0000000000001743
Type 2 diabetes and glycemia · Weight loss and obesity · Comparative effectiveness
American journal of therapeutics · 2024 Sep-Oct 01 · PMID 39292847 · DOI 10.1097/MJT.0000000000001756
Type 2 diabetes and glycemia · Weight loss and obesity · Comparative effectiveness
Medicine · 2023 Jul 7 · PMID 37417602 · DOI 10.1097/MD.0000000000034122
Type 2 diabetes and glycemia · Safety and tolerability · Mechanism and pharmacology · Comparative effectiveness
Frontiers in pharmacology · 2025 · PMID 40444045 · DOI 10.3389/fphar.2025.1438318
Comparative effectiveness
European journal of clinical investigation · 2024 Apr · PMID 37950521 · DOI 10.1111/eci.14125
Type 2 diabetes and glycemia · Weight loss and obesity
Cardiovascular diabetology · 2023 Mar 9 · PMID 36894938 · DOI 10.1186/s12933-023-01775-x
Type 2 diabetes and glycemia · Cardiovascular outcomes · Weight loss and obesity
Health science reports · 2023 Sep · PMID 37720167 · DOI 10.1002/hsr2.1549
Type 2 diabetes and glycemia · Mechanism and pharmacology
Scientific reports · 2022 Oct 31 · PMID 36316432 · DOI 10.1038/s41598-022-22263-4
Type 2 diabetes and glycemia · Safety and tolerability · Comparative effectiveness
The Journal of clinical endocrinology and metabolism · 2022 Apr 19 · PMID 34922383 · DOI 10.1210/clinem/dgab905
Dose intensification · Comparative effectiveness
Journal of clinical pharmacy and therapeutics · 2021 Oct · PMID 33675117 · DOI 10.1111/jcpt.13398
Type 2 diabetes and glycemia · Safety and tolerability · Comparative effectiveness
Molecular and cellular neurosciences · 2026 Jun · PMID 42014236 · DOI 10.1016/j.mcn.2026.104091
Mechanism and pharmacology
Clinical therapeutics · 2021 Nov · PMID 34728099 · DOI 10.1016/j.clinthera.2021.08.015
Type 2 diabetes and glycemia · Comparative effectiveness
Endocrine · 2020 Jun · PMID 31927749 · DOI 10.1007/s12020-020-02193-9
Type 2 diabetes and glycemia · Safety and tolerability · Mechanism and pharmacology
Cardiovascular diabetology · 2020 Oct 9 · PMID 33036617 · DOI 10.1186/s12933-020-01148-8
Type 2 diabetes and glycemia · Comparative effectiveness · Real-world outcomes
Nature · 2026 Apr · PMID 41407860 · DOI 10.1038/s41586-025-10031-z
Type 2 diabetes and glycemia · Comparative effectiveness
Frontiers in endocrinology · 2026 · PMID 42388875 · DOI 10.3389/fendo.2026.1843595
Type 2 diabetes and glycemia · Comparative effectiveness
Journal of diabetes investigation · 2025 May · PMID 39891527 · DOI 10.1111/jdi.14395
Type 2 diabetes and glycemia · Cardiovascular outcomes · Weight loss and obesity
Annals of internal medicine · 2025 May · PMID 40183678 · DOI 10.7326/ANNALS-24-03849
Type 2 diabetes and glycemia · Dose intensification · Comparative effectiveness
Journal of diabetes · 2025 Apr · PMID 40214296 · DOI 10.1111/1753-0407.70077
Type 2 diabetes and glycemia · Safety and tolerability · Comparative effectiveness
Diabetology & metabolic syndrome · 2025 Aug 27 · PMID 40859274 · DOI 10.1186/s13098-025-01927-x
Type 2 diabetes and glycemia
Diabetes, obesity & metabolism · 2024 Jan · PMID 37794628 · DOI 10.1111/dom.15296
Type 2 diabetes and glycemia · Weight loss and obesity · Safety and tolerability · Comparative effectiveness
Iranian journal of pharmaceutical research : IJPR · 2019 Fall · PMID 32184883 · DOI 10.22037/ijpr.2019.14733.12619
Type 2 diabetes and glycemia · Safety and tolerability · Comparative effectiveness
Diabetes, obesity & metabolism · 2017 Apr · PMID 27981757 · DOI 10.1111/dom.12849
Type 2 diabetes and glycemia · Safety and tolerability · Mechanism and pharmacology · Comparative effectiveness
European journal of endocrinology · 2026 Feb 4 · PMID 41525326 · DOI 10.1093/ejendo/lvag005
Mechanism and pharmacology
Dulaglutide evidence · ranking key
A tier describes the evidentiary role and design strength of a source. It is not a popularity score, proof that every conclusion is correct, or a substitute for claim-level review.
Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.
Smaller randomized trials, strong prospective cohorts, prespecified secondary analyses, and high-quality comparative-effectiveness studies.
Retrospective cohorts, claims-database studies, pharmacovigilance analyses, mechanistic human research, and well-documented case series.
Case reports, conference abstracts, preclinical research, hypothesis-generating analyses, and expert commentary.
APA
World Peptide Foundation. (n.d.). Dulaglutide — Peptide Scientific Intelligence. World Peptide Foundation. (Updated September 23, 2026.) https://www.worldpeptidefoundation.org/directory/dulaglutide
AMA / Vancouver
World Peptide Foundation. Dulaglutide — Peptide Scientific Intelligence. World Peptide Foundation website. Updated September 23, 2026. https://www.worldpeptidefoundation.org/directory/dulaglutide
Featured tiered studies
149
Cornerstone publications with study-level interpretation, limitations, and tier disclosure.
Research domains
12
Clinical and scientific questions synthesized independently across the evidence atlas.
Governed reviewed evidence
0
Database records promoted through the governed publication workflow—not the corpus total.
Corpus generated 2026-09-18. Counts remain separately labeled to prevent automated screening from being represented as completed human review.
Human experience · separate evidence stream
Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.
Observation is valuable human context. It is not evidence of causation, efficacy, or safety.
Public display gate
n ≥ 20 eligible observations
Exact progress remains private before the threshold.
Intelligence snapshot
A compact view of what is represented, what remains unresolved, and how completely the record can be traced.
Ranked research corpus
500
Categorized screening records; proposed rankings remain pending human appraisal.
Featured tiered studies
149
Cornerstone studies with published study-level interpretation and tier disclosure.
Research domains
12
Independent evidence dossiers covering the major research questions.
Governed reviewed evidence
0
Reviewed database records promoted through the governed publication workflow.
Contradictions
0
Conflicting evidence relationships that remain visible.
Research gaps
3
Questions the current record identifies as unresolved.
Connected media
0
Media records explicitly linked to this scientific record.
What we know
The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.
Reconciled domain conclusions
Dulaglutide no longer relies on the legacy “no public claim” state. Each research domain publishes a bounded conclusion, confidence level, evidence synthesis, limitations, geographic applicability, regulatory interpretation, and research gaps.
Inspect the reconciled evidence atlasNo reviewed published evidence records are represented for this peptide yet. This is not evidence that no research exists.
Scientific context
Existing reviewed chemistry is preserved as scientific context. Chemistry and mechanism information do not establish clinical efficacy or safety.
No reviewed chemistry record is currently represented for this peptide.
Explore further
Move from this peptide record into the project's broader evidence, research, comparison, and methodology systems.
Research
Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.
No peptide-specific research chronology has been represented yet.
The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.
No verified published evidence records are currently represented for this peptide.
Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.
A reviewed chemistry record is not currently represented.
Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.
No institutional claim record is currently represented for this peptide.
Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.
Connections
Connections appear only when they are represented by the project’s underlying records.
No structured peptide-specific connections are currently represented.
Traceability
The experience makes incomplete links visible instead of presenting a false impression of perfect provenance.
Source publication state
A governed source may be verified and approved for publication while its claim-to-evidence link is still incomplete.
Reviewer provenance state
“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.
Domain conclusion → Evidence
Connected
Evidence → Source
Connected
Source → Original record
Connected
Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.
Reconciled for 12 domain conclusions and 149 featured studies.
Detailed study-to-domain mappings and original-source paths appear in the Dulaglutide evidence-governance section.
Inspect the ranked source recordsObservational archive
Observational archive data is intentionally separated from published scientific evidence.
Observational boundary
Insufficient eligible observations are available for display under the current filters.
Insufficient eligible observations are currently represented to display aggregated findings for this peptide.
Research + media
Only media explicitly linked through the project’s relationship system appears here.
No scientifically connected media is currently represented for this peptide.
Sources + provenance
Generated: 9/24/2026, 4:02:25 AM
Tier classifies source design and evidentiary role. Confidence reflects risk of bias, sample size, comparator quality, outcome relevance, follow-up, missing data, directness, replication, reporting quality, and whether conclusions stay within the measured results.
Funding and conflicts are disclosed and considered, but sponsorship never automatically changes a tier. Corrections, retractions, and expressions of concern override the original rating.